D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC — Stella

Recruiting

Back to Intrahepatic Cholangiocarcinoma trials

Trial locations(1 site)

China

Fujian Provincial Hospital, Fuzhou, Fujian

Key details

Sponsor

Fujian Provincial Hospital

Enrollment target

~37 participants

Started

July 2024

Primary completion

January 2027

Age range

18 Years – 75 Years

Last updated June 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov